[15-12G] Third Harmonic Bio, Inc. SEC Filing

Rhea-AI Filing Summary

Third Harmonic Bio, Inc. submitted a Form 15 certifying termination of its registration under the Securities Exchange Act and suspension of periodic filing obligations. The company relied on Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i) and reported an approximate 6 holders of record. The notice was executed by Christopher Murphy, Chief Financial and Business Officer. This filing means the company will no longer be required to furnish periodic SEC reports under the Exchange Act, reducing the availability of routine public disclosures.

Insights

Corporate Governance Expert

TL;DR Deregistration under Form 15 ends routine SEC reporting, materially reducing public disclosure and shareholder transparency.

The company certified termination under Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i), reporting only six holders of record. From a governance perspective, ending periodic reporting removes regular audited and unaudited disclosures that investors rely on for oversight. While the filing is a formal compliance action, it materially changes the transparency profile and information flow available to shareholders.

Securities Analyst

TL;DR Form 15 filing suspends reporting obligations and signals a shift to reduced SEC disclosure for THRD.

Third Harmonic Bio's reliance on the cited rules and the small number of record holders (6) enables termination of its reporting duties. For market participants, this means fewer public periodic filings to track operating results, financial condition, and other material developments. The change is material for investors who depend on Exchange Act reports for timely company information.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File No. 001-41498

Third Harmonic Bio, Inc.

(Exact name of registrant as specified in its charter)

1700 Montgomery Street, Suite 210

San Francisco, California 94111

(209) 727-2457

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.0001 per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)		☒
Rule 12g-4(a)(2)		☐
Rule 12h-3(b)(1)(i)		☒
Rule 12h-3(b)(1)(ii)		☐
Rule 15d-6		☐
Rule 15d-22(b)		☐

Approximate number of holders of record as of the certification or notice date: 6

Pursuant to the requirements of the Securities Exchange Act of 1934, Third Harmonic Bio, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

				THIRD HARMONIC BIO, INC.
Date: August 11, 2025				By:		/s/ Christopher Murphy
				Name:		Christopher Murphy
				Title:		Chief Financial and Business Officer

FAQ

What action did Third Harmonic Bio (THRD) take in this filing?

THRD filed a Form 15 certifying termination of its registration under the Exchange Act and suspension of periodic filing obligations.

Which rules did Third Harmonic Bio rely on to terminate reporting?

The filing shows reliance on Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i).

How many holders of record did THRD report?

The company reported approximately 6 holders of record.

Who signed the Form 15 for Third Harmonic Bio?

The Form 15 was executed by Christopher Murphy, Chief Financial and Business Officer, on behalf of the company.

Does this filing mean THRD no longer provides SEC reports?

Yes. The Form 15 certifies termination of registration and suspension of the duty to file periodic Exchange Act reports.